Pipeline
ABL105
HomePipelineABL105
-
- Pipeline
- ABL105
-
- Program Target
- HER2x4-1BB
-
- Disease Indication
- Solid Tumor
-
- Development Stage
- Clinical Development (Phase 1)
- Summary
- ABL105 is a bispecific antibody that simultaneously targets HER2 and 4-1BB, crosslinking and activating 4-1BB signaling only in the presence of HER2 expressing tumor cells. Additionally, ABL105 blocks HER2 signaling and induces NK cell-mediated cytotoxicity, leading to stronger anti-tumor activity. ABL105 significantly inhibits tumor growth and protects mice from tumor recurrence by inducing tumor-specific immunological memory.
MOA of ABL105
ABL105 in the Grabody™-T BsAb Platform activates T-cells only in the Tumor Microenvironment
Tumor Specific 4-1BB Activation
ABL105 activates 4-1BB signaling only in the presence of tumor cells in a HER2 expression-dependent manner
Strong Anti-Tumor Effect
ABL105 inhibits tumor growth and protects mice from tumor re-challenge by inducing tumor specific memory
